Please login to the form below

Not currently logged in
Email:
Password:

Dupixent

This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

Akcea's FDA-rejected Waylivra also recommended. The EMA’s main advisory committee for medicines backed new indications for AstraZeneca and Merck &Co/MSD’s Lynparza and Sanofi’s Dupixent that ... For Sanofi and its Dupixent (dupilumab) partner

Latest news

More from news
Approximately 13 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics